Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648487 | 0.94 | CTSS (0.54) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL24187757 | 0.94 | CTSL (0.51) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL7121567 | 0.93 | CTSS (0.56) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL584447 | 0.90 | MEN1 (0.47) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL3333808 | 0.90 | TLR2 (0.47) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL3339610 | 0.90 | TLR2 (0.47) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL19641048 | 0.90 | TLR2 (0.47) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL21197875 | 0.88 | NPC1 (0.48) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL19641407 | 0.88 | CTSL (0.44) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL12070062 | 0.86 | CTSL (0.49) | CTSLCTSBCTSSLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897833-B1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2025-07-10 | — | — | US | disclosed |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-26 | — | — | US | disclosed |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-02-06 | — | — | US | disclosed |
| US-12215111-B2 | Imidazopyridazine IL-17 inhibitor compounds | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-04 | — | — | US | disclosed |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-12060346-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4408529-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| EP-3291814-B1 | AN ANTI-CANCER AGENT 1-((4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)METHYL) CYCLOPROPANAMINE, ITS CRYSTALLINE FORM AND ITS SALTS | ADVENCHEN PHARMACEUTICALS LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118146123-A | Synthesis method of An Luoti nii hydrochloride intermediate | 河北鼎泰制药有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-6566379-B1 | As proteolytic enzyme inhibitors; thrombin inhibitors; for therapy of pancreatitis, thrombosis, ischemia, stroke, restenosis, emphysema or inflammation in a mammal | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-20030087921-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6472399-B2 | ANTICOAGULANTS; MAY BE EMBEDDED IN OR PHYSICALLY LINKED TO MATERIALS USED IN MANUFACTURE OF DEVICES USED IN BLOOD COLLECTION, CIRCULATION, STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020086872-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | LU TIANBAO (US) | 2002-07-04 | — | — | US | disclosed |
| US-6350764-B2 | FOR INHIBITING LOSS OF BLOOD PLATELETS; INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, FIBRIN, THROMBUS, AND EMBOLUS; ANTICOAGULANTS EMBEDDED IN DEVICES FOR BLOOD COLLECTION, CIRCULATION, STORAGE (CATHETERS, DIALYSIS MACHINES); STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-26 | — | — | US | disclosed |
| US-20020007070-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | LU TIANBAO (US) | 2002-01-17 | — | — | US | disclosed |
| US-6245763-B1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-06-12 | — | — | US | disclosed |
| EP-1036063-A1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-09-20 | — | — | EP | disclosed |
| US-6037356-A | ANTICOAGULANTS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1999026926-A1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060346-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, SAAL1 | CTSL 68/4885CTSB 950/4885CTSS 342/4885 |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | CTSL 68/4885CTSB 950/4885CTSS 342/4885 |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | CTSL 3481/4885CTSB 3690/4885CTSS 4020/4885 |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | ERBB2, MERTK, ABL1 | CTSL 3481/4885CTSB 3690/4885CTSS 4020/4885 |
| US-12215111-B2 | Imidazopyridazine IL-17 inhibitor compounds | IL17A, IL23R, IL15 | CTSL 2339/4885CTSB 3087/4885CTSS 3561/4885 |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CTSL 2339/4885CTSB 3087/4885CTSS 3561/4885 |
| US-20020086872-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | CTSL 191/4885CTSB 199/4885CTSS 243/4885 |
| US-20020007070-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, PLAT | CTSL 158/4885CTSB 168/4885CTSS 207/4885 |
| US-20030087921-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, F2R | CTSL 137/4885CTSB 144/4885CTSS 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.